H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.08, a high estimate of ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes ...

H.C. Wainwright raised the firm’s price target on Oculis (OCS) to $32 from $29 and keeps a Buy rating on the shares. The firm says the ...

HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their previous forecast of ($0.15).

H.C. Wainwright analyst Amit Dayal lowered the firm’s price target on ClearSign (CLIR) to $2 from $6 and keeps a Buy rating on the shares. The ...

Evolus, Inc. (NASDAQ:EOLS – Free Report) – Investment analysts at HC Wainwright dropped their FY2025 earnings per share estimates for Evolus in a report released on Thursday, April 10th.

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to ...

Analysts have recently evaluated Verve Therapeutics and provided 12-month price targets. The average target is $17.5, ...

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going ...

Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.